<DOC>
	<DOCNO>NCT01272466</DOCNO>
	<brief_summary>Anti-apoptotic protein Bcl-2 family know play key role oncogenesis overexpressed myeloma cell . Studies show dendritic cell expose proteasome inhibition present exogene antigen well unexposed dendritic cell . Patients relapse multiple myeloma offer vaccination peptide derive antiapoptotic protein Bcl-2 family combination immunostimulatory adjuvant . The vaccination give relation treatment proteasome inhibitor bortezomib .</brief_summary>
	<brief_title>Vaccination With Peptides From Anti-apoptotic Proteins Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>clinical diagnosis multiple myeloma tissue type HLAA1 , HLAA2 HLAA3 Performance status &lt; 2 Adequate bone marrow renal liver function write informed concent candidate bone marrow transplantation malignancy multiple myeloma significant medical disease ( heart , lung liver disease diabetes ) allergy active autoimmune disease treatment immunosuppressive drug treatment experimental drug uncontrolled hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>vaccination</keyword>
	<keyword>antiapoptotic protein</keyword>
	<keyword>proteasome inhibition</keyword>
</DOC>